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Abstract 
CPV3, the third parvalbumin isoform to be identified in the chicken, is produced exclusively in the thymus gland. Although parvalbumins are 
typically cysteine-deficient, CPV3 contains two cysteine residues, at positions 18 and 72. The reported three-dimensional parvalbumin structures 
suggest hat the side chain of cysteine-72 should be solvent-accessible. Accordingly, we find that CPV3 readily forms disulfide-linked oligomers in 
the absence of reducing agents. The reaction, employing either 0, or ferricyanide ion as the oxidant, is apparently restricted to the Ca*+-bound form 
of the protein. The differing reactivity of the Ca*‘, Mg”, and apo-forms has significant structural implications. 
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1. Introduction 
Parvalbumins are small, vertebrate-specific proteins 
that bind two mols of Ca2’ with high affinity [1,2]. The 
metal ion-binding sites display the helix-loophelix 
structural motif common to all members of the calmod- 
ulin superfamily [3,4]. Parvalbumins are abundant in se- 
lect skeletal myofibrils and neurons and are widely 
believed to serve as cytosolic Ca2’ buffers. The parvalbu- 
min family encompasses two sub-lineages: /?-parvalbu- 
mins (PI < 5.0) and a-parvalbumins (p1 > 5.0) [5]. 
Whereas fish and amphibians express multiple skeletal 
muscle isoforms (e.g. [6,7]), postnatal mammals express 
a single muscle isoform that is also expressed in other 
tissue settings [8]. Early in mammalian development, 
however, an additional parvalbumin isoform is produced 
in the fetal placenta [93. This protein, discovered by 
MacManus [lo], has been labeled oncomodulin due to 
its frequent reappearance in neoplastic tissues (~80% of 
all mammalian tumors regardless of origin, [l 11) and its 
conjectured role as a Ca2’-dependent modulator early in 
embryological development. 
The pattern of parvalbumin expression in avian spe- 
cies differs from that observed in lower vertebrates or in 
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postnatal mammals. Although birds, like mammals, ex- 
press a single muscle parvalbumin, two distinct parval- 
bumin isoforms have been identified in the avian thymus 
gland. Avian thymic hormone (or ATH’) was the first to 
be identified [12]. Its name derives from a capacity to 
stimulate differentiation of T-cell precursors in vitro [ 131. 
A second thymic parvalbumin, labeled CPV3, was re- 
cently discovered by this lab [14]. The cDNAs for both 
proteins have been cloned [15,16]. Both are /?-parvalbu- 
mins and show 52% sequence identity. The CPV3 se- 
quence is identical to that of oncomodulin at 73 of 108 
positions. 
Although parvalbumins are characteristically deficient 
in cysteine, CPV3 contains two cysteine residues, at posi- 
tions 18 and 72. The side-chain of Cys”, a characteristic 
feature of B-parvalbumins [171, is part of the hydropho- 
bic core. Due to its relative inaccessibility [18-201, Cys” 
is unreactive toward sulfhydryl reagents in the Ca2’- 
bound forms of oncomodulin [21], carp parvalbumin 
[22,23], and perch parvalbumin [24]. However, inspec- 
tion of the existing /3-parvalbumin X-ray structures 
[18-20,25,26] suggests that CYS’~, on the other hand, 
should be solvent-accessible. In view of the potential role 
of CPV3 as an extracellular signaling factor, we have 
investigated its capacity for forming disulfide-linked 
dimers. Our results indicate that the reactivity of the 
Ca”-bound forms differs significantly from that of the 
apo- or Mg2’-bound forms. 
2. Materials and methods 
Chicken thymus glands were purchased from Pel-Freez Biologicals. 
The following supplies were purchased from Sigma Chemical Co.: 
Sephadex G-25, Sephadex G-75, acrylamide, N,N’-methylene- 
his-acrylamide, N,N,N,llr-tetramethyle thylenediamine, ammonium 
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persulfate, DTNB, HEPES, MES, DTT, ampicillin, LB broth, ly- 
sozyme, phenylmethylsulfonyl fluoride, 2-mercaptoethanol, and xyle- 
no] orange. SDS, MgCl,.6H,O, CaC1,.2H,O, Na,EDTA, and a stand- 
ard Cal’ solution were obtained from Fisher Scientific. Protein molec- 
ular weight standards were purchased from Bio-Rad. TbCI, was pur- 
chased from Aldrich Chemical Co. 
CPV3 was isolated from chicken thymus tissue as described elsewhere 
[27]. Expression of CPV3 in Escherichia coli DHSa_was driven by the 
lac promoter of Bluescript (Stratagene). High level expression of onco- 
modulin has been achieved in this laboratory employing a Bluescript- 
based vector that we call pLD2 [28]. Reasoning that CPV3 would be 
expressed at similarly high levels in this construction, we shuttled the 
CPV3 coding sequence into the pLD2 vector, preserving the relative 
placement of the promoter elements, the ShineeDalgarno sequence, and 
the initiator codon. The resulting plasmid is called pHZ1. Routine 
recombinant DNA manipulations were performed in accordance with 
Maniatis et al. [29]. 
Isolation of the recombinant protein was carried out as described 
previously for the tissue-derived protein [27]. One gram of cell paste 
yields 2-3 mg of purified protein. The purified protein contains 1.9-2.0 
equivalents of Ca’+, as determined by atomic absorption. 
Thiol-protecting reagents (dithiothreitol or 2-mercaptoethanol) were 
removed from the CPV3 preparations by gel-filtration on Sephadex 
G-25 in 0.15 M NaCI, 0.025 M HEPES-NaOH, pH 7.4. Prior to loading 
the 1 .O ml protein sample (10 mg/ml), the column (1.0 cm x 28 cm bed, 
equipped with flow adapter) was equilibrated with buffer that had been 
thoroughly deoxygenated with N,. The eluate was monitored at 280 nm. 
Reductant-free CPV3 eluted well ahead of the excess reductant and was 
collected in a nitrogen-filled serum bottle. 
The sulfhydryl content of the CPV3 preparation was determined with 
Ellman’s reagent [28], as described previously [21]. CPV3 concentra- 
tions were determined by titration with Tb’+, monitoring the sensitized 
emission that accompanies binding of the lanthanide. Since the titra- 
tions level off abruptly upon addition of two molar equivalents of TbS’, 
the protein concentration can be determined to within 5%. The Tb” 
titrant was standardized by titration with EDTA at pH 6.0 [31]. 
Unless otherwise specified, the oligomerization reactions were stud- 
ied at room temperature. Samples were quick-frozen and stored at 
-80°C prior to electrophoresis. Although CPV3 is isolated as the Ca*+ 
complex, additional Ca” (1 .O mM) was generally added when examin- 
ing the behavior of the Ca*+-bound species, to insure that both sites 
were completely occupied. To study the behavior of apo-CPV3, excess 
EDTA (2 mM) was included in the dimerization solution. The Mg*‘- 
bound form of the protein was produced by adding 2 mM EGTA and 
20 mM Mg*+ ion. 
Dimerization was monitored by SDS-PAGE. Following a pre- 
electrophoresis step (to remove residual persulfate ion), the 15 ~1 sam- 
ples were underlayered with a syringe. Reductant was omitted from the 
SDS sample buffer, and the protein samples were not boiled prior to 
loading. The reservoir buffer was 0.025 M Tris, 0.20 M glycine, and 
EDTA (0.001 M) was included in the anode buffer. Gels were stained 
with Coomassie brilliant Blue R250. 
3. Results 
The translated cDNA sequence provided the first sug- 
gestion that CPV3 might contain a reactive cysteine res- 
idue [16]. In addition to Cys”, a characteristic of 
/3-parvalbumin isoforms, CPV3 also displayed a cysteine 
residue at position 72. The reported parvalbumin struc- 
tures [l&20,25,26] indicate that the side-chain of this 
residue should be solvent-accessible. For purposes of 
illustration, the conformation of oncomodulin in the 
vicinity of Ser” is displayed in Fig. 1A. It is clear from 
this representation that Ser’* resides in a /?-turn at the 
end of helix D and that the side-chain hydroxyl is ori- 
ented toward the solvent. Based on its high degree of 
sequence identity with oncomodulin (73 of 108 residues), 
we would expect the polypeptide chain of CPV3 to adopt 
a similar conformation, rendering Cys’* solvent-accessi- 
ble and potentially capable of participating in a disulfide- 
mediated dimerization reaction. 
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Fig. 1. (A) The side-chain of residue 72 is solvent-accessible. The conformation of oncomodulin in the vicinity of residue 72 is displayed above. The 
X-ray crystallographic structure of the Ca*‘-bound form of oncomodulin (20) was downloaded from the Brookhaven Protein Data Bank and displayed 
with SYBYL (Tripos Associates, St. Louis, MO). In CPV3, Serine-72 is replaced by cysteine. (B) Dimerization of CPV3 during storage at -20°C. 
This reductant-free preparation of CPV3 had been stored at -2OOC for a period of several months prior to analysis by SDS-PAGE. Lane A, 2 pg 
of CPVS, untreated. Lane B, 2 lug of CPV3, treated with 10 mM DTT for 10 min at room temperature prior to electrophoresis. The observed mobilities 
for select molecular weight standards are indicated at center. 
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Fig. 2 (A) Oxygen-mediated oligomerization of CPV3. Samples of reductant-free CPV3 (2OOpM) were incubated at room temperature for 48 h under 
conditions designed to yield either the apo-, Me-, or Ca2’-bound forms of the protein. 6 ,~l aliquots were then analyzed by SDS-PAGE. Lane A, 
no addition; lane B, 1 .O mM Ca”; lane C, 2.0 mM EDTA; lane D, 2.0 mM EGTA plus 20 mM Mg’+. (B) Ferricyanide-mediated oligomerization 
of CPV3. Potassium ferricyanide was added to samples of CPV3 (200pM) to afford a final concentration of 5 mM. Solution conditions were chosen 
to yield either the apo-, Mg”, or Ca*‘-bound forms of the protein. After 5 min at room temperature, 6~1 samples were resolved by SDS-PAGE. 
Lane A, no ferricyanide added; lane B, ferricyanide plus 1 .O mM Ca*+; lane C, ferricyanide plus 2.0 mM EDTA; lane D, ferricyanide plus 2.0 mM 
EGTA and 20 rnk Mg’+. 
We, therefore, examined a CPV3 solution that had 
been stored at -20°C in the absence of reductant for a 
prolonged period of time. The majority of the prepara- 
tion displayed an A4, of about 30,000, consistent with 
formation of a covalent dimer (Fig. lB, lane A). Treat- 
ment with DTT resulted in quantitative conversion back 
to the monomeric species (Fig. lB, lane B), indicating 
that a disulfide linkage provided the covalent cross-link. 
Initial attempts to monitor the dimerization reaction 
were plagued by irreproducibility. We subsequently de- 
duced that the variability was correlated with a reduced 
sulfhydryl content. Presumably, the diminished sulfhy- 
dry1 content resulted from side-reactions, notably the 
production of cysteic acid, between the reductant-free 
CPV3 and atmospheric 0,. To minimize these putative 
side-reactions, excess reductant was removed by gel-fil- 
tration on columns that had been thoroughly equili- 
brated with deoxygenated buffer, and the reductant-free 
CPV3 was collected in N,-filled serum bottles. More- 
over, to avoid exposure of the protein to high O2 concen- 
trations at the air-solution interface, the CPV3 was intro- 
duced via syringe into the incubation vessel under a layer 
of mineral oil. The latter precaution insured a gradual 
introduction of 0, into the CPV3 solution. 
With these measures taken, the dimerization behavior 
became reproducible. The reductant-free protein col- 
lected after passage through the G-25 column contains 
2.0 mol of -SH. After gradual exposure to oxygen, virtu- 
ally all of the protein is converted into higher molecular 
weight species. The results of a typical experiment are 
presented in Fig. 2A. In this experiment, reductant-free 
CPV3 was incubated for periods up to 48 h under condi- 
tions designed to afford either apo-, Ca*+, or Mg’+- 
bound forms of the protein (see above). 
In the presence of 1 mM Ca*‘, nearly all of the mon- 
omeric CPV3 is converted to higher molecular weight 
species after 48 h (Fig. 2A, lane B). In fact, it is not 
necessary to introduce additional Ca*+ into the reaction 
to promote disulfide-bond formation. As isolated, the 
protein contains roughly 2.0 equivalents of Ca”, and this 
level is sufficient to facilitate oligomerization (Fig. 2A, 
lane A) . By contrast, in the presence of excess EDTA 
(Fig. 2A, lane C) or M$’ (Fig. 2A, lane D), the protein 
remains almost entirely monomeric. These data indicate 
that the Ca”-bound form of the protein dimerizes much 
more readily than either the apo- or Mg*‘-bound forms 
of the protein. 
We have also examined the relative rates of CPV3 
dimerization employing ferricyanide as the oxidant. Fer- 
ricyanide is a relatively mild oxidant that is often used 
to promote disulfide-bond formation during protein re- 
folding experiments [32]. The results, displayed in Fig. 
2B, are consistent with the O,-driven oxidation studies 
discussed above. The rate of reaction is greatly increased, 
but the pattern of reactivity is identical. Intermolecular 
disulfide bridges are formed to a significant extent only 
in the presence of free Ca*’ (Fig. 2B, lane B). The levels 
of dimer present in the apo- (lane C) and Mg*‘-bound 
(lane D) samples of CPV3 are comparable to that seen 
in the untreated control (lane A). 
Notice that trimers and higher multimers are evident 
as well as dimers on the acrylamide gels shown in 
Fig. 2. Initially, we thought that these species arose dur- 
ing electrophoresis because they are more prominent 
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Fig. 3. (A) Gel-filtration of oxidized CPV3 preparation. A 1.0 ml sample of reductant-free CPV3 (180 ,uM) that had been incubated for 72 h at room 
temperature was loaded onto a G-75 column (1.5 x 47 cm) that had been equilibrated with 0.15 M NaCl, 0.025 M HEPES-NaOH, pH 7.4, and eluted 
at 20 ml/h with the same buffer. 10 ~1 aliquots of the 1 .O ml fractions were immediately analyzed by SDS-PAGE. Lanes A-M correspond to fractions 
49 through 61. (B) Effect of temperature on the extent of oligomerization. Samples of reductant-free CPV3 (180 PM) were incubated either at -20°C 
(lane A), 4°C (lane B), or 23°C (lane C) for 48 h in the presence of 1 .O mM Ca*‘. 2.0 .uI aliquots were removed for analysis by SDS-PAGE. 
when the pre-electrophoresis omitted. However, if an 
oxidized CPV3 preparation is subjected to gel-filtration 
chromatography on Sephadex G-75, the fractions 
(Fig. 3A, lanes A-F) eluting just ahead of the dimeric 
material (lanes F-K) display substantial amounts of 
higher molecular weight complexes. We conclude from 
this result that the multimeric species are present in the 
oxidized preparation prior to electrophoresis. 
If CPV3 oxidation is allowed to occur at lower temper- 
atures, oligomerization is halted at the dimer stage. Sam- 
ples of CPV3 that had been incubated for 48 h at either 
-20°C 4°C or room temperature (23°C) were examined 
by SDS-PAGE (Fig. 3B). The samples that had been 
incubated at the lower temperatures display only mono- 
mer and dimer bands (lanes A and B, respectively). By 
contrast, the sample incubated at room temperature 
(lane C) displays a prominent band with a molecular 
weight corresponding to a crosslinked trimer, in addition 
to the dimer band. 
Parenthetically, the doublets that are visible on the 
polyacrylamide gels may reflect modification of cysteine 
and/or methionine residues by oxygen or by reactive 
species in the polyacrylamide matrix, either during the 
incubation period or transit through the stacking gel. 
These non-specific oxidative events could alter the SDS 
content of the SDS-protein micelles, thereby modulating 
their electrophoretic mobilities. The detergent content of 
SDS-parvalbumin complexes is clearly sensitive to 
amino acid sequence. For example, the three known 
chicken parvalbumin isoforms, although very similar in 
molecular weight, exhibit apparent molecular weights 
ranging from 12,000 to 15,000 by SDS-PAGE [14,16]. 
4. Discussion 
The experiments described above reveal that the thy- 
mus-specific hicken parvalbumin called CPV3 is capa- 
ble of forming intermolecular disulfide crosslinks. At low 
temperatures (either 4” or -20°C) disulfide-mediated 
crosslinking terminates at the dimer stage (Fig. 3B). Pre- 
sumably, this species reflects formation of a disulfide 
bridge between the Cys7* sulfhydryl groups of two CPV3 
monomers, symbolized (18*72)-(72* 18). Interestingly, 
however, exposure of reductant-free CPV3 to oxygen at 
room temperature results in the appearance of trimers 
and higher multimers. 
We surmise that these larger complexes are produced 
by disulfide-bond formation between the CYSTS sulfhy- 
dry1 of a CPV3 monomer and one of the Cys” residues 
in the dimer. Although Cys18 is largely inaccessible, the 
data of Ahmed et al. [20] indicate that the sulfhydryl 
group of that residue is connected to the protein surface 
by a narrow channel roughly 6 A deep. This channel may 
allow the sulfhydryl of CYS’~ to approach sufficiently 
closely for reaction to occur. The putative structure of 
the trimeric species afforded by this reaction is symbol- 
ized (18*72)-(72* 18)-(72* 18). Note that the predominant 
dimeric and trimeric species lack free Cys7* sulfhydryl 
groups and, thus, cannot condense to form larger com- 
plexes. Rather, they can only serve as acceptors in the 
polymerization process. In all likelihood, depletion of 
the monomer pool limits chain-elongation largely to the 
trimer stage. The absence of multimeric species at the 
reduced incubation temperatures may reflect reduced 
conformational mobility and/or insufficient thermal en- 
ergy for the reaction between Cys” and Cys’*. 
Significantly, CPV3 forms oligomers only in the pres- 
ence of Ca2’. The apo-and Mg2’-bound forms of the 
protein both exhibit a very limited capacity for intermol- 
ecular crosslinking. The contrasting behavior observed 
for the apo- and Ca*‘-bound forms is not unexpected. 
UV difference spectroscopy [33], circular dichroism [24], 
proton magnetic resonance [34], chemical modification 
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[Zl-241, and differential scanning calorimetry [35] all 
indicate that the apo-protein is less ordered than the 
Ca”-bound form. The loss of structure that accompanies 
Ca*’ removal in the B-parvalbumins is more prominent 
than in the a-isoforms [36] and may reflect the greater 
electrostatic repulsion of the more acidic I-isoforms. 
A priori, there are two potential explanations for the 
difference in oligomerization behavior observed for the 
Ca*’ and Mg2’-bound forms of CPV3. It is possible that 
Mg2’ ion is not bound at one or both sites. Alternatively, 
the Ca2’-bound conformation of the protein may differ 
significantly from the Mg”-bound form of the protein. 
Unpublished work from this lab (Zhao, H., Hapak, R.C. 
and Henzl, M.T., unpublished data) indicates that both 
sites will be occupied at the concentration of Mg2’ em- 
ployed in the oligomerization studies. Thus, the disulfide 
crosslinking experiments lend strong support to spectro- 
scopic data indicating that Ca2’ and Mg2’-bound forms 
of parvalbumins may adopt perceptibly different confor- 
mations. 
This subject has been a topic of considerable interest 
over the years. Early UV difference measurements [33] 
and proton magnetic resonance [34] experiments re- 
vealed perceptible spectroscopic alterations upon Ca2’- 
Mg2+ exchange. The crystal structure of pike parvalbu- 
min (p1 4.1) complexed with Mg2+ at the EF site, re- 
ported by Declercq et al. [25], offered a structural basis 
for these differences. Specifically, Glu”’ is converted 
from a bidentate ligand in the Ca2’ complex to a mon- 
odentate ligand in the Mg2+ complex. Similar differences 
were recently observed in solution by Blancuzzi et al. in 
their detailed 2D-NMR analysis of pike parvalbumin III 
[371. 
The extent of the structural changes that accompany 
Ca2+-Mg2+ exchange remains a matter of conjecture. Al- 
though the chemical shift differences observed by Blan- 
cuzzi et al. [37] are largely confined to the CD and EF 
ion-binding loops, there are pronounced changes in the 
amide proton shifts for Lysa and Glu’03. These residues 
are located in the D and F helices, respectively, imme- 
diately adjacent to the ion-binding loops. The observed 
chemical shift alterations suggest that their secondary 
structures differ perceptibly in the Ca” and Mg2+-com- 
plexed forms of the protein and that the difference in 
Ca2’ and Mg2’-coordination geometry is relayed, at 
least, to the first several residues of the flanking C-termi- 
nal helical element. In this context, Hutnik et al. [38] 
noted that the fluorescence behavior of Trp”’ in cod 
parvalbumin differs markedly in the Ca*‘- and Mg2+- 
bound forms. 
The oligomerization studies described herein suggest 
that, at least for the B-parvalbumin known as CPV3, the 
conformational alteration accompanying Ca2’-Mg” ex- 
change is transmitted the entire length of the D helix to 
the B-turn involving residues 71-74. 
Since the biological function of CPV3 is unknown, we 
cannot state whether the observed oligomerization reac- 
tions have any physiological significance. Inside the cell, 
CPV3 would undoubtedly be present in monomeric 
form, due to the high intracellular concentration of glu- 
tathione. In the extracellular milieu, however, dimeriza- 
tion could occur and would, in fact, be favored by the 
high Ca2’ concentrations. It has been suggested that 
ATH plays an extracellular signaling role. If CPV3 func- 
tions similarly, then the intermolecular crosslinking reac- 
tion could have some biological consequence. It is 
known, for example, that SlOOp forms a disulfide-linked 
dimer and that the dimeric form of the protein is a potent 
stimulator of nerve growth [39]. However, the parallel 
between CPV3 and the SIOO system is not exact. Whereas 
the S 100 proteins normally exist as non-covalent dimers, 
parvalbumins are monomeric. The physiological rele- 
vance, if any, of the oligomerization reaction is a subject 
for future investigations. 
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